BD Ups R&D Spending, Focusing On Drug Delivery And Diabetes Research
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson is investing in research on the use of micro-needles and needleless technologies in advanced drug delivery systems
You may also be interested in...
BD’s R&D Pipeline Includes Micro-Needle Drug Delivery; Q4 Sales Up 8%
BD is preparing for functionality testing of its development-stage Micro Infuser wearable drug-delivery system, incorporating micro-needles to deliver drugs just below the skin's surface to minimize pain
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.